nach oben

Erschienen in:

01.03.2016 | Original Article

Radiotherapy of spinal cord gliomas

A retrospective mono-institutional analysis

verfasst von: Dr. med. Stefanie Corradini, MD, Indrawati Hadi, MD, Vinzent Hankel, MD, Lorenz Ertl, MD, MSc, Ute Ganswindt, MD, Claus Belka, MD, Maximilian Niyazi, MD, MSc

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Due to the rarity of spinal cord gliomas, no consensus has been reached regarding the optimal treatment strategy. The aim of the present retrospective study was to identify patient and tumor characteristics and to evaluate the effectiveness of radiotherapy within this setting.

Patients and methods

Patients diagnosed with spinal cord gliomas between 2003 and 2013 and treated at the Department of Radiation Oncology, University of Munich, were retrospectively analyzed. Overall survival was estimated with the Kaplan–Meier method and univariate analysis was performed by log-rank testing.

Results

A total of 16 patients were identified. The cohort consisted of seven primary spinal cord gliomas and eight cases of metastases of cerebral gliomas. Median follow-up was 42 months and median total radiation dose was 45.0 Gy. In all, 62.5 % of patients received a simultaneous chemotherapy with temozolomide. The median overall survival was 6 months (95% CI: 0–27.5 months). Surgical resection of the tumor was a significant predictor of improved survival, compared with radiotherapy alone (p = 0.001). Patients with the diagnosis of a primary spinal cord glioma survived significantly longer than those presenting with a metastatic deposit from a cerebral glioma (p < 0.001). A statistically significant dose–response relationship at dose levels of ≥ 45 Gy vs. < 45 Gy could be derived (p < 0.001). Simultaneous chemotherapy did not influence survival outcome.

Conclusion

Despite the aggressive treatment in the present study, the prognosis for spinal cord gliomas was still poor, with a median overall survival of 6 months. To the best of our knowledge, this is the largest study reporting the results of simultaneous chemoradiation in spinal cord gliomas. A combined chemoradiation treatment seems feasible and can be considered as a new treatment option in the management of spinal cord gliomas.

Henson JW (2001) Spinal cord gliomas. Curr Opin Neurol 14:679–682CrossRefPubMed

Rodrigues GB, Waldron JN, Wong CS et al (2000) A retrospective analysis of 52 cases of spinal cord glioma managed with radiation therapy. Int J Radiat Oncol Biol Phys 48:837–842CrossRefPubMed

Nowak-Sadzikowska J, Gliński B (2002) The value of postoperative radiotherapy of primary spinal cord glioma. Rep Pract Oncol Radiother 7:139–147CrossRef

Abdel-Wahab M, Etuk B, Palermo J et al (2006) Spinal cord gliomas: a multi-institutional retrospective analysis. Int J Radiat Oncol Biol Phys 64:1060–1071CrossRefPubMed

Zorlu F, Ozyigit G, Gurkaynak M et al (2005) Postoperative radiotherapy results in primary spinal cord astrocytomas. Radiother Oncol 74:45–48CrossRefPubMed

Shirato H, Kamada T, Hida K et al (1995) The role of radiotherapy in the management of spinal cord glioma. Int J Radiat Oncol Biol Phys 33:323–328CrossRefPubMed

Kahn J, Loeffler JS, Niemierko A et al (2011) Long-term outcomes of patients with spinal cord gliomas treated by modern conformal radiation techniques. Int J Radiat Oncol Biol Phys 81:232–238CrossRefPubMed

Robinson CG, Prayson RA, Hahn JF et al (2005) Long-term survival and functional status of patients with low-grade astrocytoma of spinal cord. Int J Radiat Oncol Biol Phys 63:91–100CrossRefPubMed

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRefPubMed

10.

Karim AB, Maat B, Hatlevoll R et al (1996) A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36:549–556CrossRefPubMed

11.

Balducci M, Fiorentino A, De Bonis P et al (2013) Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials. Strahlenther Onkol 189:926–931CrossRefPubMed

12.

Lawton CD, Nagasawa DT, Yang I et al (2012) Leptomeningeal spinal metastases from glioblastoma multiforme: treatment and management of an uncommon manifestation of disease. J Neurosurg Spine 17:438–448CrossRefPubMed

13.

Niyazi M, Schwarz SB, Suchorska B et al (2012) Radiotherapy with and without temozolomide in elderly patients with glioblastoma. Strahlenther Onkol 188:154–159CrossRefPubMed

14.

Flieger M, Ganswindt U, Schwarz SB et al (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol 117:337–345CrossRefPubMed

15.

Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708PubMedCentralCrossRefPubMed

16.

Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722CrossRefPubMed

17.

Niyazi M, Jansen NL, Rottler M et al (2014) Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. Radiat Oncol 9:299PubMedCentralCrossRefPubMed

18.

Fietkau R, Putz F, Lahmer G et al (2013) Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time? A word of caution. Strahlenther Onkol 189:993–995CrossRefPubMed

19.

Chamberlain MC, Tredway TL (2011) Adult primary intradural spinal cord tumors: a review. Curr Neurol Neurosci Rep 11:320–328CrossRefPubMed

20.

Raco A, Esposito V, Lenzi J et al (2005) Long-term follow-up of intramedullary spinal cord tumors: a series of 202 cases. Neurosurgery 56:972–981 (discussion 972–981)PubMed

21.

Mcgirt MJ, Goldstein IM, Chaichana KL et al (2008) Extent of surgical resection of malignant astrocytomas of the spinal cord: outcome analysis of 35 patients. Neurosurgery 63:55–60 (discussion 60–51)CrossRefPubMed

22.

Sandler HM, Papadopoulos SM, Thornton AF Jr et al (1992) Spinal cord astrocytomas: results of therapy. Neurosurgery 30:490–493CrossRefPubMed

23.

Minehan KJ, Brown PD, Scheithauer BW et al (2009) Prognosis and treatment of spinal cord astrocytoma. Int J Radiat Oncol Biol Phys 73:727–733CrossRefPubMed

24.

Isaacson SR (2000) Radiation therapy and the management of intramedullary spinal cord tumors. J Neurooncol 47:231–238CrossRefPubMed

25.

Garcia DM (1985) Primary spinal cord tumors treated with surgery and postoperative irradiation. Int J Radiat Oncol Biol Phys 11:1933–1939

26.

Marks LB, Yorke ED, Jackson A et al (2010) Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 76:10–19PubMedCentralCrossRefPubMed

27.

Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122CrossRefPubMed

28.

Kirkpatrick JP, Van Der Kogel AJ, Schultheiss TE (2010) Radiation dose–volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 76:42–49CrossRefPubMed

29.

Linstadt DE, Wara WM, Leibel SA et al (1989) Postoperative radiotherapy of primary spinal cord tumors. Int J Radiat Oncol Biol Phys 16:1397–1403CrossRefPubMed

30.

Shaw EG, Evans RG, Scheithauer BW et al (1986) Radiotherapeutic management of adult intraspinal ependymomas. Int J Radiat Oncol Biol Phys 12:323–327CrossRefPubMed

31.

Muller K, Schlamann A, Guckenberger M et al (2014) Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group. Strahlenther Onkol 190:377–381CrossRefPubMed

32.

Muller K, Schlamann A, Seidel C et al (2013) Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma. A compassionate use treatment. Strahlenther Onkol 189:693–696CrossRefPubMed

33.

Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343PubMedCentralCrossRefPubMed

34.

Chamberlain MC (2008) Temozolomide for recurrent low-grade spinal cord gliomas in adults. Cancer 113:1019–1024CrossRefPubMed

35.

Kaley TJ, Mondesire-Crump I, Gavrilovic IT (2012) Temozolomide or bevacizumab for spinal cord high-grade gliomas. J Neurooncol 109:385–389CrossRefPubMed

36.

Chamberlain MC, Johnston SK (2011) Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab. J Neurooncol 102:427–432CrossRefPubMed

37.

Tseng HM, Kuo LT, Lien HC et al (2010) Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide. Anticancer Drugs 21:963–967CrossRefPubMed

38.

Kim WH, Yoon SH, Kim CY et al (2011) Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review. J Neurooncol 101:247–254CrossRefPubMed

Titel: Radiotherapy of spinal cord gliomas
A retrospective mono-institutional analysis
verfasst von: Dr. med. Stefanie Corradini, MD
Indrawati Hadi, MD
Vinzent Hankel, MD
Lorenz Ertl, MD, MSc
Ute Ganswindt, MD
Claus Belka, MD
Maximilian Niyazi, MD, MSc
Publikationsdatum: 01.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 3/2016
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-015-0917-0

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Radiotherapy of spinal cord gliomas

A retrospective mono-institutional analysis

Abstract

Background

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Temporal changes in tumor oxygenation and perfusion upon normo- and hyperbaric inspiratory hyperoxia

Reduziertes Rezidivrisiko im Bestrahlungsareal durch adjuvante Strahlentherapie bei lymphogen metastasierten malignen Melanomen mit hohem regionärem Rezidivrisiko

Automatically gated image-guided breath-hold IMRT is a fast, precise, and dosimetrically robust treatment for lung cancer patients

Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients

Primary glioblastoma multiforme tumors and recurrence

Kardiale Toxizität von Trastuzumab in der adjuvanten Therapie von Mammakarzinompatientinnen

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie